IMMUNOCHEMOTHERAPY WITH OBINUTUZUMAB OR RITUXIMAB IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA IN THE RANDOMIZED PHASE III GALLIUM STUDY: ANALYSIS BY CHEMOTHERAPY REGIMEN

被引：0
|
作者：
Hiddemann, W. [1 ]
Barbui, A. M. [2 ]
Albendea, M. A. Canales [3 ]
Cannell, P. K. [4 ]
Collins, G. P. [5 ]
Duerig, J. [6 ]
Forstpointner, R. [1 ]
Herold, M. [7 ]
Hertzberg, M. [8 ]
Klanova, M. [9 ,10 ,11 ]
Radford, J. A. [12 ,13 ]
Tobinai, K. [14 ]
Burciu, A. [15 ]
Fingerle-Rowson, G. R. [11 ]
Nielsen, T. [11 ]
Wolbers, M. [16 ]
Marcus, R. E. [17 ]
机构：
[1] Ludwig Maximilians Univ Munchen, Dept Med 3, Munich, Germany
[2] Azienda Osped Papa Giovanni XXIII, Dept Hematol, Bergamo, Italy
[3] Hosp Univ la Paz, Dept Med, Madrid, Spain
[4] Fiona Stanley Hosp, Dept Haematol, Murdoch, WA, Australia
[5] Churchill Hosp, Oxford Canc & Haematol Ctr, Dept Clin Haematol, Oxford, England
[6] Univ Klinikum Essen, Med Fac Haematol, Essen, Germany
[7] HELIOS Klinikum Erfurt, Ctr Oncol, Erfurt, Germany
[8] Prince Wales Hosp, Dept Haematol, Sydney, NSW, Australia
[9] Charles Univ Prague, Fac Med 1, Gen Hosp, Prague, Czech Republic
[10] Charles Univ Prague, Inst Pathol Physiol, Prague, Czech Republic
[11] F Hoffmann La Roche Ltd, Pharma Dev Clin Oncol, Basel, Switzerland
[12] Univ Manchester, Manchester, Lancs, England
[13] Christie NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England
[14] Natl Canc Ctr, Dept Hematol, Tokyo, Japan
[15] F Hoffmann La Roche Ltd, Pharma Dev Safety & Risk Management, Basel, Switzerland
[16] F Hoffmann La Roche Ltd, Pharma Dev Biometr Biostat, Basel, Switzerland
[17] Kings Coll Hosp London, Dept Haematol, London, England
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
S775
引用
收藏
页码：314 / 314
页数：1
相关论文
共 50 条
  • [31] Results of a Phase II Study of Obinutuzumab in Combination with Lenalidomide in Previously Untreated, High Tumor Burden Follicular Lymphoma (FL)
    Nastoupil, Loretta J.
    Westin, Jason R.
    Hagemeister, Fredrick B.
    Lee, Hun Ju
    Fayad, Luis
    Samaniego, Felipe
    Ahmed, Sairah
    Claret, Linda
    Steiner, Raphael E.
    Nair, Ranjit
    Parmar, Simrit
    Rodriguez, Maria Alma
    Wang, Michael L.
    Green, Michael R.
    Davis, Eric
    Neelapu, Sattva S.
    Fowler, Nathan H.
    BLOOD, 2019, 134
  • [32] SAKK 35/15: A phase I trial of obinutuzumab with venetoclax in previously untreated follicular lymphoma patients
    Stathis, A.
    Mey, U.
    Mach, N.
    Krasniqi, F.
    Hitz, F.
    Hohloch, K.
    Bertoni, F.
    Rondeau, S.
    Vilei, S. Berardi
    Eckhardt, K.
    Zucca, E.
    SWISS MEDICAL WEEKLY, 2018, 148 : 2S - 3S
  • [33] Equivalent efficacy of a biosimilar rituximab and reference rituximab in previously untreated advanced follicular lymphoma: Extended results of ASSIST-FL, a confirmatory phase III study
    Jurczak, W.
    Moreira, I.
    Govindbabu, K. Setty
    Munhoz, E.
    Echeveste, M-A.
    Giri, P.
    Castro, N.
    Pereira, J.
    Luiza, A.
    Alexeev, S.
    Osmanov, D.
    Zhu, P.
    Alexandrova, S.
    Zubel, A.
    Harlin, O.
    Amersdorffer, J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [34] COST EFFECTIVENESS OF OBINUTUZUMAB PLUS CHEMOTHERAPY FOLLOWED BY OBINUTUZUMAB MAINTENANCE FOR PATIENT WITH PREVIOUSLY UNTREATED ADVANCED-STAGE FOLLICULAR LYMPHOMA IN FRENCH SETTING
    Mazaleyrat, B.
    Boissard, F.
    Ayad, S.
    Launonen, A.
    VALUE IN HEALTH, 2020, 23 : S438 - S438
  • [35] Safety and Efficacy of Atezolizumab in Combination with Obinutuzumab and Bendamustine in Patients with Previously Untreated Follicular Lymphoma: An Interim Analysis
    Younes, Anas
    John, Burke M.
    Diefenbach, Catherine S.
    Ferrari, Silvia
    Kahn, Cyrus
    Sharman, Jeffrey P.
    Tani, Monica
    Ujjani, Chaitra S.
    Vitolo, Umberto
    Yuen, Sam
    Woodard, Paul
    Mundt, Kirsten
    Fingerle-Rowson, Gunter
    Chitra, Surya
    Sellam, Gila
    Morariu-Zamfir, Rodica
    Gilbertson, Michael
    BLOOD, 2017, 130
  • [36] PRELIMINARY SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF DUVELISIB PLUS RITUXIMAB OR OBINUTUZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED CD20+FOLLICULAR LYMPHOMA
    Casulo, C.
    Jacobsen, E.
    Van Eygen, K.
    Holmes, H. E.
    Lemmens, J. P.
    Allen, K.
    Steelman, L.
    Campbell, V.
    Nevejans, J.
    Pearlberg, J.
    Goy, A.
    HAEMATOLOGICA, 2016, 101 : 104 - 104
  • [37] COST-EFFECTIVENESS ANALYSIS OF OBINUTUZUMAB FOR THE TREATMENT OF PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED FOLLICULAR LYMPHOMA IN GREECE
    Vellopoulou, K.
    Tzanetakos, C.
    Theodoropoulou, T.
    Akratos, A.
    Maniadakis, N.
    VALUE IN HEALTH, 2018, 21 : S38 - S38
  • [38] Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA study
    Bachy, Emmanuel
    Houot, Roch
    Feugier, Pierre
    Bouabdallah, Krimo
    Bouabdallah, Reda
    Virelizier, Emmanuelle Nicolas
    Maerevoet, Marie
    Fruchart, Christophe
    Snauwaert, Sylvia
    Le Gouill, Steven
    Marolleau, Jean-Pierre
    Molina, Lysiane
    Molucon-Chabrot, Cecile
    Thieblemont, Catherine
    Tilly, Herve
    Bijou, Fontanet
    Haioun, Corinne
    Van den Neste, Eric
    Fabiani, Bettina
    Meignan, Michel
    Cartron, Guillaume
    Salles, Gilles
    Casasnovas, Olivier
    Morschhauser, Franck
    BLOOD, 2022, 139 (15) : 2338 - 2346
  • [39] SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma
    Stathis, Anastasios
    Mey, Ulrich
    Schar, Sami
    Hitz, Felicitas
    Pott, Christiane
    Mach, Nicolas
    Krasniqi, Fatime
    Novak, Urban
    Schmidt, Christian
    Hohloch, Karin
    Kienle, Dirk Lars
    Hess, Dagmar
    Moccia, Alden A.
    Unterhalt, Michael
    Eckhardt, Katrin
    Hayoz, Stefanie
    Forestieri, Gabriela
    Rossi, Davide
    Dirnhofer, Stefan
    Ceriani, Luca
    Sartori, Giulio
    Bertoni, Francesco
    Buske, Christian
    Zucca, Emanuele
    Hiddemann, Wolfgang
    BLOOD ADVANCES, 2022, 6 (13) : 3911 - 3920
  • [40] Comparison of Efficacy and Safety of Biosimilar CT-P10 to Rituximab in Patients with Previously Untreated Low Tumor Burden Follicular Lymphoma (LTBFL): A Randomized Phase III Study
    Ogura, Michinori
    Manuel Sancho, Juan
    Cho, Seok-Goo
    Nakazawa, Hideyuki
    Suzumiya, Junji
    Tumyan, Gayane
    Kim, Jin Seok
    Lennard, Anne
    Mariz, Jose Mario
    Ilyin, Nikolai
    Jurczak, Wojciech
    Lopez Martinez, Aurelio
    Samoilova, Olga
    Zhavrid, Edvard
    Yanez Ruiz, Eduardo
    Trneny, Marek
    Popplewell, Leslie
    Coiffier, Bertrand
    Buske, Christian
    Kim, Won Seog
    Lee, SangJoon
    Lee, Sungyoung
    Bae, Yunju
    Kwak, Larry W.
    BLOOD, 2018, 132
12345